Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support antiplatelet use post-MI in diabetes but should not change practice; leaves open confirmation in larger trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Deepak L. Bhatt (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: